Plus Therapeutics, Inc.

PSTV

US72941H5090

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.69 ^USD	+1.50%		+3.68%	-3.43%

Apr. 22	Plus Therapeutics Gets $3 Million Funding Recommendation From Department of Defense	MT
Apr. 22	Plus Therapeutics, Inc. Receives $3 Million Award Recommendation from the United States Department of Defense	CI

Plus Therapeutics, Inc. authorizes a Buyback Plan.

October 30, 2023

The Board of Directors of Plus Therapeutics, Inc. has authorized a buyback plan on October 31, 2023.

Latest news about Plus Therapeutics, Inc.

Plus Therapeutics Gets $3 Million Funding Recommendation From Department of Defense	Apr. 22	MT
Plus Therapeutics, Inc. Receives $3 Million Award Recommendation from the United States Department of Defense	Apr. 22	CI
Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic	Mar. 25	CI
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	Mar. 11	CI
Transcript : Plus Therapeutics, Inc., Q4 2023 Earnings Call, Mar 05, 2024	Mar. 05
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
North American Morning Briefing : S&P 500 Futures -2-	Mar. 05	DJ
Transcript : Plus Therapeutics, Inc. - Special Call	Nov. 20
Plus Therapeutics, Inc. Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting	Nov. 20	CI
Top Premarket Gainers	Nov. 03	MT
Plus Therapeutics Shares Jump Premarket on FDA Orphan Designation	Nov. 03	DJ
Plus Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Calendar Year of 2024	23-10-31	CI
Transcript : Plus Therapeutics, Inc., Q3 2023 Earnings Call, Oct 31, 2023	23-10-31
Plus Therapeutics, Inc. announces an Equity Buyback for $0.5 million worth of its shares.	23-10-31	CI
Plus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
Plus Therapeutics, Inc. authorizes a Buyback Plan.	23-10-30	CI
Plus Therapeutics, Inc. Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	23-10-10	CI
Sector Update: Health Care Stocks Slipping Late Friday8 Afternoon	23-09-08	MT
Sector Update: Health Care Stocks Slipping Friday Afternoon	23-09-08	MT
Sector Update: Health Care	23-09-08	MT
Biocept Signs Non-Exclusive Licensing Agreement With Plus Therapeutics on CNSide Tumor Cell Platform	23-09-08	MT
Wall Street Set to Open Flat Friday as Investors Remain Wary of Potential Interest Rate Hike	23-09-08	MT
Top Premarket Gainers	23-09-08	MT
Plus Therapeutics, Inc. Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase	23-09-05	CI
Transcript : Plus Therapeutics, Inc., Q2 2023 Earnings Call, Aug 14, 2023	23-08-14

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Plus Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.69 USD

Average target price

11.33 USD

Spread / Average Target

+570.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PLUS THERAPEUTICS, INC.	-3.43%	7.23M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research